Novartis announced today updated results from the landmark COMBI-AD clinical trial, demonstrating that treatment with Tafinlar® (dabrafenib) and Mekinist® (trametinib) following the surgical removal of melanoma offers a long-term and durable relapse-free survival (RFS) benefit to high-risk patients diagnosed with stage III, BRAF-mutation positive melanoma1. Researchers reported that 52% (95% CI, 48%-58%) of patients treated with adjuvant Tafinlar + Mekinist were alive and relapse-free at five years.
source https://www.pharmatutor.org/pharma-news/2020/novartis-announces-long-term-relapse-free-survival-benefit-for-high-risk-stage-iii-melanoma-patients-treated-with-tafinlar-mekinist-following-surgery
No comments:
Post a Comment